Kamala Harris

Joe Biden

Dean Phillips

Marianne Williamson

Donald Trump

Vivek Ramaswamy

Nikki Haley

Ron DeSantis

Cornel West

Robert F. Kennedy

2024 United States Presidential Election

The government and Eli Lilly are partnering to conduct a five-year real-world trial called Surmount-Real UK to evaluate the weight loss drug tirzepatide’s impact on health outcomes and employment status. The study will focus on weight loss, prevention of obesity-related complications, quality of life, and changes in employment status and sick days. The trial will be conducted in partnership with Health Innovation Manchester and the University of…

Eli Lilly

Dataemia

Weight loss drugs for the unemployed—how will the government’s new trial work?

Scientists have discovered a new process in our immune systems that leads to the production of an important family of anti-viral proteins called interferons. They hope the discovery will now lead to new, effective therapies for people with some autoimmune and infectious diseases.Researchers have found that a natural metabolite called Itaconate can stimulate immune cells to make interferons by blocking an enzyme called SDH.

Science Daily

'Two for the price of one' Scientists discover new process to drive anti-viral immunity

Eli Lilly and Company (NYSE:LLY) Shares Up 0.6%  - What's Next?

marketbeat.com

Eli Lilly and Company (NYSE:LLY) Stock Price Up 0.6%  - Time to Buy?

In the billion-dollar obesity market, Eli Lilly and Novo Nordisk have a big lead, but there are opportunities for the 23 pursuers. ‘The market is still in its infancy. So there is room for improvement.’

De Tijd

Obesity medication of the future: more powerful, easier and fewer side effects

Haya Therapeutics, a biotech based in Lausanne, signs an agreement with Eli Lilly to develop targeted therapies against obesity. A promising collaboration, of up to 1 billion dollars, which relies on RNA to revolutionize treatments.

Switzerland

pme.ch

Haya Therapeutics signs deal with Eli Lilly

Questions in the pharmacy are endless and often hard to answer.

Ozempic

Novo Nordisk

Diabetes

Alzheimer's Disease

Pharmacy Times

Concerns Linger About GLP-1 Inhibitors Despite Their Popularity

The United Kingdom, together with the pharmaceutical company Eli Lilly, plans to give the green light for its public health system to start administering the drug Mounjaro to up to 250,000 obese and unemployed people, in order to [...]

Obesity

United Kingdom

MM Medical

This is Mounjaro, the drug that the United Kingdom plans to administer to the unemployed with obesity

Eli Lilly has announced the appointment of Thomas J Fuchs as its first chief artificial intelligence (AI) officer. Fuchs’ appointment comes into effect 21 October 2024, later this month. The role, the first of its kind at Eli Lilly, will include oversight of AI initiatives amongst the company’s activities. Such activities include clinical trials, manufacturing, […] The post Eli Lilly appoints new chief AI officer appeared first on Pharmafile.

Artificial Intelligence

Indianapolis

pharmafile.com

Eli Lilly appoints new chief AI officer - Pharmafile

Quartz

ETF Daily News

tickerreport.com

CNBC

Benzinga

Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high rate of long-term sickness that has become a major drag on the economy.

tag:reuters.com,2012:binary_TM3E8AF0R9O01-BASEIMAGE

Europe

European Economy

UK Politics

Economy

European Politics

Politics

UK Economy

Medical

BBC News

The Independent

Daily Express

Daily Mirror

Hindustan Times

Britain to study use of weight loss drug to get people back to work

Jabs used for weight loss and treating type 2 diabetes could help people with alcohol abuse problems, according to a study. The injections led to a 50% lower rate of alcohol intoxication in people taking them compared to those who had not been prescribed them, researchers found.

7055770

Science

Diet

New York City

CBS News

Newsweek

Washington Examiner

Sky News UK

Weight loss drugs could help people with alcohol addiction, study suggests

The Food and Drug Administration (FDA) said it will reconsider its decision to remove Eli Lilly’s blockbuster weight loss and diabetes drug from its official shortage list and allow compounding pharmacies to continue selling their own versions. 



News from Eli Lilly